Urological Cancer: Clinical Advances in Personalized Therapy

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 25 May 2025 | Viewed by 1124

Special Issue Editors


E-Mail Website
Guest Editor
Division of Urology, IRCCS Azienda Ospedaliero—Universitaria di Bologna, 40138 Bologna, Italy
Interests: minimally invasive surgery; RARP; RAPN; RARC; prostate cancer; renal cancer; urothelial cancer; robotic platforms

E-Mail Website
Guest Editor
Department of Urology, IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, 20089 Milan, Italy
Interests: diagnosis and treatment of urologic malignancies; robotic surgery; surgical training
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, the field of urology has witnessed a transformative shift towards minimally invasive surgical techniques, with robot-assisted surgery at the forefront of this evolution. This innovation has expanded the scope of minimally invasive procedures, extending its applications from oncological treatments to the management of benign diseases. At the same time, significant development has occurred in terms of pharmacological approaches, with the advent of novel drugs designed to target various urologic malignancies with unprecedented precision.

Against this backdrop, we are excited to announce this Special Issue dedicated to showcasing the latest clinical advancements in pursuing personalized therapy for urological tumors. We invite contributions that not only highlight technological and therapeutic breakthroughs but also shed light on how these developments are paving the way for customized treatment plans tailored to each patient’s unique needs.

Dr. Angelo Mottaran
Dr. Marco Paciotti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • minimally invasive surgery
  • robot-assisted surgery
  • immunotherapy
  • prostate cancer
  • renal cancer
  • urothelial cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

23 pages, 480 KiB  
Systematic Review
High-Intensity Focus Ultrasound Ablation in Prostate Cancer: A Systematic Review
by Che-Hsueh Yang, Daniela-Viviana Barbulescu, Lucian Marian, Min-Che Tung, Yen-Chuan Ou and Chi-Hsiang Wu
J. Pers. Med. 2024, 14(12), 1163; https://doi.org/10.3390/jpm14121163 - 20 Dec 2024
Viewed by 779
Abstract
Background/Objectives: Prostate cancer (PCa) outcomes vary significantly across risk groups. In early-stage localized PCa, the functional outcomes following radical prostatectomy (RP) can be severe, prompting increased interest in focal therapy, particularly High-Intensity Focused Ultrasound (HIFU). This study is to summarize the current clinical [...] Read more.
Background/Objectives: Prostate cancer (PCa) outcomes vary significantly across risk groups. In early-stage localized PCa, the functional outcomes following radical prostatectomy (RP) can be severe, prompting increased interest in focal therapy, particularly High-Intensity Focused Ultrasound (HIFU). This study is to summarize the current clinical trials of HIFU on PCa. Methods: We reviewed clinical trials from major databases, including PubMed, MEDLINE, Scopus, and EMBASE, to summarize the current research on HIFU in PCa treatment. Results: The literature highlights that HIFU may offer superior functional outcomes, particularly in continence recovery, compared to RP and radiation therapy. However, the oncological efficacy of HIFU remains inadequately supported by high-quality studies. Focal and hemigland ablations carry a risk of residual significant cancer, necessitating comprehensive patient counseling before treatment. For post-HIFU monitoring, we recommend 3T magnetic resonance imaging (MRI) with biopsy at 6 to 12 months to reassess the cancer status. Biochemical recurrence should be defined using the Phoenix criteria, and PSMA PET/CT can be considered for identifying recurrence in biopsy-negative patients. Conclusions: Whole-gland ablation is recommended as the general approach, as it provides a lower PSA nadir and avoids the higher positive biopsy rates observed after focal and hemigland ablation in both treated and untreated lobes. Future study designs should address heterogeneity, including variations in recurrence definitions and surveillance strategies, to provide more robust evidence for HIFU’s oncological outcomes. Full article
(This article belongs to the Special Issue Urological Cancer: Clinical Advances in Personalized Therapy)
Show Figures

Figure 1

Back to TopTop